Spirecut participated in the Swissnex Startup Camp in Boston from November 3–7, 2025, a program powered by Innosuisse. The week focused on practical U.S. market entry—covering fundraising, regulatory strategy, reimbursement, and legal considerations—culminating in a public pitch to Boston-area investors and clinical innovators.
Our Boston week at a glance
Monday, Nov 3 — Market immersion
Spirecut joined an orientation on the U.S. medtech landscape and mapped an initial partner funnel. Sessions covered hospital purchasing dynamics, outpatient surgery center economics, and the timeline from evaluation to adoption for new surgical techniques.
Tuesday, Nov 4 — Regulatory & reimbursement deep dive
Workshops centered on U.S. regulatory pathways applicable to ultrasound-guided carpal tunnel release, addressing evidence expectations, human factors, labeling, and physician training requirements. A reimbursement session outlined coding, coverage, and payment for carpal tunnel procedures, and how clinical endpoints (pain, function, return-to-work) support payer discussions.
Wednesday, Nov 5 — Medtech Pitchfest 2025
Spirecut presented its minimally invasive, implant-free technique for carpal tunnel syndrome to investors, clinicians, and industry leaders. The pitch emphasized ultrasound guidance, precise ligament release without open surgery, and the potential for shorter recovery and reduced scarring. Follow-up conversations explored study design for U.S. sites and commercialization milestones.
Thursday, Nov 6 — Legal, IP, and commercial readiness
Spirecut worked through U.S. corporate, commercial, and IP topics: clinical collaboration agreements, data use, surgeon training materials, and trademark considerations. Commercial sessions focused on distributor models, direct versus hybrid sales, and post-market evidence generation.
Friday, Nov 7 — 1:1 mentoring and field feedback
Spirecut held targeted meetings with advisors and prospective partners to pressure-test the U.S. clinical development plan, refine surgeon onboarding, and prioritize early adopter centers. The team left with a clear action list for pilot evaluations and KOL engagement.
What we showcased
Spirecut’s technique offers minimally invasive, implant-free treatment for carpal tunnel syndrome using a proprietary ultrasound-guided cutting device. The approach enables precise ligament release without open surgery, designed to reduce recovery time and scarring while maintaining procedural control under ultrasound visualization.
Key takeaways from the week
Regulatory & clinical evidence: Defined the evidence package needed for U.S. adoption, including procedural safety metrics and validated functional outcomes.
Reimbursement path: Clarified coding and documentation requirements for outpatient settings and how to align studies with payer expectations.
Commercial model: Prioritized an initial focus on surgeon training, site certification, and a phased rollout with early adopter centers.
Surgeon onboarding: Formalized a training pathway combining ultrasound proficiency, simulated practice, and proctored cases.
On stage at Medtech Pitchfest 2025
Spirecut presented on Wednesday, November 5, highlighting clinical value, workflow fit, and the plan for U.S. post-market evidence. The team engaged with investors and clinical stakeholders on next steps for pilot studies and distribution strategy.
Next steps
Following the program, Spirecut began scoping U.S. pilot evaluations, advancing discussions with advisors on study protocols, and exploring commercial partnerships to support surgeon training and site readiness.
